Roche/ArQule Enter E2F Oncology Alliance; Roche Licensing Likely At Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
The partnership gives ArQule $15 mil. up-front plus additional funding for its E2F oncology program. The firm hopes to be the first to market with an E2F-targeted agent.
You may also be interested in...
ArQule Gets $30 Million Up Front From Kyowa In Oncology Deal
ArQule's agreement with Tokyo biotech Kyowa to develop and commercialize Phase I oncology molecule ARQ 197 in Asia will give the firm a much-needed cash infusion to support the product's development in the U.S
ArQule Gets $30 Million Up Front From Kyowa In Oncology Deal
Agreement with Japanese firm to develop and commercialize Phase I c-Met inhibitor ARQ 197 in Asia provides much-needed cash infusion.
ArQule Gets $30 Million Up Front From Kyowa In Oncology Deal
Agreement with Japanese firm to develop and commercialize Phase I c-Met inhibitor ARQ 197 in Asia provides much-needed cash infusion.